Pfizer Inc.
COMBINATION OF A PD-1 ANTAGONIST AND A VEGFR INHIBITOR FOR TREATING CANCER
Last updated:
Abstract:
The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a VEGFR inhibitor, and the use of the combination therapies for the treatment of cancer, and in particular for treating cancers that express PD-L 1.
Status:
Application
Type:
Utility
Filling date:
14 Jan 2020
Issue date:
15 Oct 2020